Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer

Summary

This is an open-label, Phase 1b study which will be conducted in two parts: part A is the dose escalation study while part B is dose expansion study. The purpose of the dose escalation part is to identify the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of CM082 combined with paclitaxel in patients with advanced gastric cancer who did not respond to first-line standard chemotherapy. In the subsequent dose expansion part, additional subjects will be enrolled to further explore the safety and preliminary clinical activity of CM082 and paclitaxel.

Timeline

Start

2018-03-15

Primary completion

2019-08

Completion

2020-08

Drugs

Indications